Journal of Clinical Virology, published by Elsevier, stands at the forefront of virology research, focusing on the clinical implications of viral diseases. With an impressive impact factor representative of its Q1 categorization in both Infectious Diseases and Virology, this journal is essential for researchers and healthcare professionals aiming to keep pace with evolving knowledge and treatments in virology. Since its inception in 1998, it has provided a vital platform for the dissemination of significant breakthroughs, now continuing through to 2024. The journal boasts competitive Scopus ranks, placing it in the 95th percentile for Infectious Diseases and the 91st percentile for Virology. Scholars can benefit from its selective Open Access options, promoting widespread access to cutting-edge research. With an ever-increasing demand for innovative solutions to viral infections, Journal of Clinical Virology remains dedicated to fostering advancements in the field, making it a key resource for anyone invested in virology and infectious disease management.

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

Archives of Virology is a prestigious academic journal dedicated to the field of virology, published by Springer Wien. Established in 1975, this journal has been a crucial platform for disseminating innovative research findings and advancements in the understanding of viral diseases and their impact on human health. It holds a notable position in the academic landscape, with a 2023 impact factor placing it in Q2 within the field of Medicine (miscellaneous) and Q3 in Virology. Its Scopus ranking within the Virology category further underscores its relevance, with a notable percentile of 45th. Although it does not provide Open Access options, the journal's rigorous peer-review process ensures the highest quality of published work, making it an essential resource for researchers, professionals, and students aiming to stay updated in the rapidly evolving field of virology. For those committed to advancing their understanding of viruses and viral diseases, Archives of Virology is a vital scholarly resource.

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

AIDS RESEARCH AND HUMAN RETROVIRUSES, published by Mary Ann Liebert, Inc., is a pivotal journal dedicated to advancing the field of HIV research and the broader spectrum of human retroviruses. With an ISSN of 0889-2229 and an E-ISSN of 1931-8405, this journal has been in continuous publication since 1987 and is respected in the academic community for its rigorous peer-reviewed articles. As a Q3 ranked journal in Immunology, Infectious Diseases, and Virology as of 2023, it plays a crucial role in disseminating cutting-edge research, theoretical advancements, and clinical insights that contribute significantly to the understanding and treatment of HIV and related disorders. The journal's objective is to foster collaboration among researchers, healthcare professionals, and educators by providing a platform for the exchange of innovative ideas and findings. Although not an open-access journal, its compelling content ensures that it remains a primary resource for those in the academic and medical communities tackling the challenges posed by retroviral infections. With a commitment to excellence and relevance, AIDS RESEARCH AND HUMAN RETROVIRUSES continues to shape the future of research in this critical area.

Hepatitis Monthly, published by BRIEFLAND in the Netherlands, is a pivotal journal in the fields of hepatology and infectious diseases. Established in 2007, it continues to make significant contributions to the understanding and management of hepatitis and related viral infections with a publication timeline extending through to 2024. Aiming to disseminate high-quality research, the journal serves as a forum for groundbreaking studies and innovations essential for healthcare professionals, researchers, and students alike. While it currently holds Q4 rankings in both hepatology and infectious disease categories, its ongoing commitment to addressing pressing health issues makes it an important resource in the academic community. Although it operates under a traditional access model, Hepatitis Monthly not only publishes original research articles, reviews, and case studies but also encourages the exchange of knowledge that helps shape future research directions and clinical practices. As it continues to explore the complexities surrounding viral hepatitis, this journal invites researchers to contribute to its mission of advancing scientific understanding and improving patient care.

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

The JOURNAL OF VIRAL HEPATITIS, published by WILEY, is a leading international journal dedicated to the dissemination of cutting-edge research in the fields of hepatology, infectious diseases, and virology. Established in 1994, this esteemed journal has created a significant impact within the scientific community, reflected by its ranking in the Q1 category for infectious diseases and Q2 for both hepatology and virology in the most recent quartile rankings. The journal provides an essential platform for scholars and practitioners to share their findings on viral hepatitis, enhancing our understanding of its pathogenesis, epidemiology, and treatment options. With its impact factor reflecting a robust citation record, the JOURNAL OF VIRAL HEPATITIS remains indispensable for those engaged in research and clinical practice regarding viral hepatitic infections. Researchers can access the journal through traditional subscription routes, underlining its commitment to advancing knowledge and fostering collaboration among scientists worldwide. As it approaches its convergence with new findings and innovative methodologies by 2024, the journal looks forward to continuing its pivotal role in shaping the future of hepatology research.